High-Specificity In Vivo Tumor Imaging Using Bioorthogonal NIR-IIb Nanoparticles

Area of Science:

• Biomedical Imaging
• Nanotechnology
• Bioorthogonal Chemistry

Background:

• Lanthanide-based probes are suitable for in vivo near-infrared-IIb (NIR-IIb) imaging.
• Current NIR-IIb probes lack sufficient tumor-targeting specificity, hindering clinical application.
• Developing highly specific nanoprobes is crucial for advanced in vivo diagnostics.

Purpose of the Study:

• To develop and evaluate bioorthogonal nanoprobes for enhanced in vivo NIR-IIb luminescence and magnetic resonance imaging (MRI).
• To assess the tumor-targeting specificity and imaging performance of these dual-modality nanoprobes.
• To demonstrate the utility of bioorthogonal chemistry in improving nanoprobe efficacy and safety.

Main Methods:

• Synthesis of dual-modality nanoprobes utilizing bioorthogonal chemistry.
• In vivo NIR-IIb luminescence imaging and MRI in murine models with subcutaneous tumors.
• Evaluation of probe enhancement (20-fold for NIR-IIb, twofold for MRI) compared to non-bioorthogonal counterparts.
• Imaging of orthotopic brain tumors to assess applicability in complex anatomical regions.

Main Results:

• Bioorthogonal nanoprobes demonstrated significantly enhanced NIR-IIb emission and MRI signal.
• High tumor-targeting specificity was achieved, outperforming non-bioorthogonal probes.
• Successful imaging of orthotopic brain tumors was accomplished.
• Reduced nanoprobe dosage was feasible due to enhanced efficacy, leading to lower cytotoxicity.

Conclusions:

• Bioorthogonal chemistry provides a powerful strategy to enhance nanoprobe performance for in vivo imaging.
• These novel nanoprobes offer superior tumor-targeting specificity and dual-modality imaging capabilities.
• The developed probes represent a significant advancement for real-time, in vivo tumor visualization with improved safety profiles.